130 related articles for article (PubMed ID: 9495704)
21. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.
Andersen JT; Nickel JC; Marshall VR; Schulman CC; Boyle P
Urology; 1997 Jun; 49(6):839-45. PubMed ID: 9187688
[TBL] [Abstract][Full Text] [Related]
22. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia.
Kuo HC
Urol Int; 1998; 60(2):85-91. PubMed ID: 9563145
[TBL] [Abstract][Full Text] [Related]
24. Comparison of efficacy between Tamsulosin and Finasteride on symptomatic Benign Prostatic Hyperplasia.
Hasan M; Parveen F; Shamsuzzaman AK; Kibria MD
Mymensingh Med J; 2007 Jul; 16(2):154-9. PubMed ID: 17703151
[TBL] [Abstract][Full Text] [Related]
25. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
26. Re: The treatment of gross hematuria secondary to prostatic bleeding with finasteride.
Sorrentino F; Sorrentino M
J Urol; 1998 Dec; 160(6 Pt 1):2164. PubMed ID: 9817358
[No Abstract] [Full Text] [Related]
27. [Long-term effect of finasteride on high-risk patients with benign prostatic hyperplasia after implantation of thermo-expandable spiral prostatic stent].
Yi XM; He HW; Xu S; Zeng T; Han DH; Zhou WQ; Ge JP; Xue S
Zhonghua Nan Ke Xue; 2022 Dec; 28(12):1065-1070. PubMed ID: 37846625
[TBL] [Abstract][Full Text] [Related]
28. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
[TBL] [Abstract][Full Text] [Related]
29. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
de la Taille A
Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085
[TBL] [Abstract][Full Text] [Related]
30. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
[TBL] [Abstract][Full Text] [Related]
31. Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience.
Chueh SC; Yu HJ; Chiu TY; Huang CY; Lai MK
J Formos Med Assoc; 1996 Aug; 95(8):650-2. PubMed ID: 8870441
[TBL] [Abstract][Full Text] [Related]
32. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.
Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
34. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
[TBL] [Abstract][Full Text] [Related]
35. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
Peters DH; Sorkin EM
Drugs; 1993 Jul; 46(1):177-208. PubMed ID: 7691505
[TBL] [Abstract][Full Text] [Related]
36. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
37. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012
[TBL] [Abstract][Full Text] [Related]
38. Post-coital gross hematuria: an unusual presentation of benign prostatic hyperplasia.
Chen YH; Lin PY; Cheng YS; Lin JS; Lin YM
Asian J Androl; 2007 Nov; 9(6):856-8. PubMed ID: 17968474
[TBL] [Abstract][Full Text] [Related]
39. Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.
Eri LM; Tveter KJ
Drugs Aging; 1997 Feb; 10(2):107-18. PubMed ID: 9061268
[TBL] [Abstract][Full Text] [Related]
40. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
